by Dennis Weissman & Associates, LLC | Mar 1, 2019 | Clinical Laboratory
In enacting the Eliminating Kickbacks in Recovery Act of 2018 (EKRA) late last year, the U.S. Congress approved an unprecedented expansion of federal anti-kickback authority. EKRA adds an all payor anti-kickback rule to the health care fraud law concerning improper...
by Dennis Weissman & Associates, LLC | Nov 16, 2018 | Clinical Laboratory, Hospital Laboratories
Starting next year, U.S. clinical laboratories including hospital outreach labs are facing a number of significant challenges now that the Centers for Medicare & Medicaid Services has made a significant change in its new market-based pricing system (PAMA) that...
by Dennis Weissman & Associates, LLC | Mar 28, 2018 | Clinical Laboratory
Get ready for some major market challenges ahead in the $97 billion U.S. laboratory industry according to a new research report, “The U.S. Clinical Laboratory Industry Forecast & Trends 2018-2020,” published by Laboratory Economics. Among the counter...
by Dennis Weissman & Associates, LLC | Oct 23, 2017 | Clinical Laboratory
Rising out-of-pocket costs by healthcare consumers are creating a major financial challenge for all types of providers including laboratories and anatomic pathology groups which are seeing growing bad debt directly attributable to the increasing numbers of patients in...
by Dennis Weissman & Associates, LLC | Oct 16, 2017 | Clinical Laboratory
Medicare reimbursement to clinical laboratories would be severely reduced under preliminary payment amounts for laboratory tests paid under a new market-based Clinical Laboratory Fee Schedule (CLFS) as required by the Protecting Access of Medicare Act of 2014 (PAMA)....
